Crinetics - Developing Therapies For Rare Endocrine Diseases

We Are Crinetics

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Read the Latest

May 12, 2022

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Crinetics reported financial results for the first quarter 2022 and outlined recent progress, including Phase 1 readout from CRN04777, licensing agreement with SKK, and strengthened management team and balance sheet.

May 10, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces Inducement Grants The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Pipeline

We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:

Acromegaly
Neuroendocrine tumors (NETs)
Carcinoid syndrome
Congenital hyperinsulinism (congenital HI)
Syndromic hyperinsulinism (syndromic HI)
Cushing’s disease
Congenital adrenal hyperplasia (CAH)

Our once-daily, oral, investigational drug for the treatment of acromegaly is in Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.

See the science >